XML 30 R11.htm IDEA: XBRL DOCUMENT
v3.20.2

Acquisition, Equity-Method Investment and Licensing Arrangements | 6 Months Ended
--- | ---
Jun. 28, 2020
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract] |
Acquisition, Equity-Method Investment and Licensing Arrangements | Acquisition, Equity-Method Investment and Licensing Arrangements A. Acquisition Array BioPharma Inc. On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred for Array was approximately $11.2 billion ($10.9 billion, net of cash acquired). Array’s portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib). The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized. B. Equity-Method Investment Formation of GSK Consumer Healthcare Joint Venture On July 31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a 32% equity stake in the new company and GSK owns the remaining 68%. Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of $8.1 billion ($5.4 billion, net of tax) in our fiscal third quarter of 2019 in (Gain) on completion of Consumer Healthcare JV transaction for the difference in the fair value of our 32% equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements. Our financial results, and our Consumer Healthcare segment’s operating results, for the second quarter of 2019 reflect three months of Consumer Healthcare segment operations and for the first six months of 2019 reflect six months of Consumer Healthcare segment operations, while financial results for the second quarter and first six months of 2020 do not reflect any contribution from the Consumer Healthcare business. We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our investment in GSK Consumer Healthcare is approximately $15.4 billion as of June 28, 2020 and $17.0 billion as of December 31, 2019 and is reported as a private equity investment in the Equity-method investments line in our condensed consolidated balance sheet. We record our share of earnings from the GSK Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in Other (income)/deductions––net commencing from August 1, 2019. Therefore, we recorded our share of the joint venture’s earnings generated in the first quarter of 2020, which totaled approximately $129 million, in our operating results in the second quarter of 2020. Our total share of the joint venture’s earnings generated in the fourth quarter of 2019 and the first quarter of 2020, which we recorded in our operating results for the first six months of 2020, was approximately $140 million. See Note 4. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately $15.7 billion and that 32% of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately $11.2 billion, resulting in an initial basis difference of approximately $4.5 billion. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in Other (income)/deductions––net commencing August 1, 2019. During the fourth quarter of 2019, GSK Consumer Healthcare revised the initial carrying value of the net assets of the joint venture and our 32% share of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was reduced to approximately $11.0 billion and our initial basis difference was increased to approximately $4.8 billion. The adjustment was allocated to equity method goodwill within the investment account. The amortization of these basis differences for the first quarter of 2020 totaling approximately $4 million of expense is included in our operating results in Other (income)/deductions––net in the second quarter of 2020. The total amortization of these basis differences for the fourth quarter of 2019 and the first quarter of 2020, which was included in our operating results in the first six months of 2020, was approximately $48 million of expense. See Note 4. Amortization of basis differences on inventory and related deferred tax liabilities has been completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives of the underlying assets, which range from 6 to 20 years. GSK Consumer Healthcare is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in Other comprehensive income. The decrease in the value of our investment from December 31, 2019 to June 28, 2020 is primarily due to approximately $1.1 billion in pre-tax foreign currency translation adjustments (see Note 6), as well as a dividend of approximately $519 million, which was received from the GSK Consumer Healthcare joint venture in June 2020. As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was $274 million for the second quarter of 2019 and $554 million for the six months ended June 30, 2019.
Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and six months ending March 31, 2020, the most recent period available, is as follows:
(MILLIONS OF DOLLARS) |  | March 31, 2020 |
Current assets |  | $ | 8,213 |
Noncurrent assets |  | 37,627 |
Total assets |  | $ | 45,840 |
Current liabilities |  | $ | 5,524 |
Noncurrent liabilities |  | 5,152 |
Total liabilities |  | $ | 10,677 |
Equity attributable to shareholders |  | $ | 35,031 |
Equity attributable to noncontrolling interests |  | 133 |
Total net equity |  | $ | 35,163 |
(MILLIONS OF DOLLARS) |  | Three Months Ended March 31, 2020 |  |  | Six Months Ended March 31, 2020 |
Net sales |  | $ | 3,503 |  |  | $ | 6,691 |
Cost of sales |  | (1,394 | ) |  | (3,205 | )
Gross profit |  | $ | 2,109 |  |  | $ | 3,486 |
Income from continuing operations |  | 425 |  |  | 471 |
Net income |  | 425 |  |  | 471 |
Income attributable to shareholders |  | 405 |  |  | 441 |
C. Licensing Arrangements Agreement with Valneva SE On April 30, 2020, we signed an agreement to co-develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15. VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of $308 million in cash payments consisting of a $130 million upfront payment, which was paid and recorded in Research and development expenses in our fiscal second quarter of 2020, as well as $35 million in development milestones and $143 million in early commercialization milestones. Under the terms of the agreement, Valneva will fund 30% of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization. Agreement with BioNTech SE On April 9, 2020, we signed a global agreement with BioNTech to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech’s proprietary mRNA vaccine platforms, with the objective of ensuring rapid worldwide access to the vaccine, if approved. The collaboration will leverage our broad expertise in vaccine R&D, regulatory capabilities, and global manufacturing and distribution network. In connection with the agreement, we paid BioNTech an upfront cash payment of $72 million, which was recorded in Research and development expenses in our fiscal second quarter of 2020, and we made an equity investment of $113 million in common stock of BioNTech. BioNTech is eligible to receive potential future milestone payments of up to $563 million for a total consideration of $748 million. While Pfizer and BioNTech will share development costs equally if the vaccine is approved and successfully commercialized, Pfizer will be responsible for all of the development costs until commercialization of the vaccine. Thereafter, BioNTech would repay Pfizer its 50 percent share of these development costs through reductions in gross profit sharing and milestone payments to BioNTech over time. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd) if development is successful and regulatory approval is obtained. We made an additional investment of $50 million in common stock of BioNTech as part of an underwritten equity offering by BioNTech, which closed in July 2020 in our fiscal third quarter of 2020.

X
- Definition Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract] + References No definition available. + Details
Name: | pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract
Namespace Prefix: | pfe_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement Disclosure [Text Block] + References No definition available. + Details
Name: | pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementDisclosureTextBlock
Namespace Prefix: | pfe_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration